Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies

Details for Australian Patent Application No. 2005244211 (hide)

Owner Allergan, Inc.

Inventors Nivaggioli, Thierry; Huang, Glenn T.

Agent Davies Collison Cave

Pub. Number AU-B-2005244211

PCT Pub. Number WO2005/110380

Priority 10/836,880 30.04.04 US

Filing date 21 April 2005

Wipo publication date 24 November 2005

Acceptance publication date 26 May 2011

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/110380 Priority application(s): WO2005/110380

26 May 2011 Application Accepted

  Published as AU-B-2005244211

22 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005244213-Intravitreal implants in conjunction with photodynamic therapy to improve vision

2005244207-Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity